Dupilumab Subcutaneous and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Dupilumab Subcutaneous and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: dupilumab
Brand name: Dupixent
Synonyms: Dupilumab
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dupilumab Subcutaneous-Insulin degludec
- Dupilumab Subcutaneous-Insulin Degludec (U-100) Prefilled Pens
- Dupilumab Subcutaneous-Insulin Degludec (U-100) Vials
- Dupilumab Subcutaneous-Insulin Degludec (U-200) Prefilled Pens
- Dupilumab Subcutaneous-Insulin degludec and liraglutide
- Dupilumab Subcutaneous-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Dupixent
- Insulin aspart, recombinant Subcutaneous-Duplex T Topical
- Insulin aspart, recombinant Subcutaneous-Durachol
- Insulin aspart, recombinant Subcutaneous-Duraclon
- Insulin aspart, recombinant Subcutaneous-Duraclon injection
- Insulin aspart, recombinant Subcutaneous-Duraflu